Treatment of Allergic Asthma with Monoclonal Anti-IgE Antibody
Open Access
- 23 December 1999
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 341 (26) , 1966-1973
- https://doi.org/10.1056/nejm199912233412603
Abstract
Immune responses mediated by IgE are important in the pathogenesis of allergic asthma. A recombinant humanized monoclonal antibody (rhuMAb-E25) forms complexes with free IgE and blocks its interaction with mast cells and basophils. We studied the efficacy of rhuMAb-E25 as a treatment for moderate-to-severe allergic asthma.Keywords
This publication has 30 references indexed in Scilit:
- The Mast Cell: A Versatile Effector Cell for a Challenging WorldInternational Archives of Allergy and Immunology, 1997
- Characterization of Complex Formation by Humanized Anti-IgE Monoclonal Antibody and Monoclonal Human IgEBiochemistry, 1995
- Anti-lgE Monoclonal Antibodies that Inhibit Allergen-Specific Histamine ReleaseInternational Archives of Allergy and Immunology, 1995
- Inhibition of Allergic Reactions with Antibodies to IgEInternational Archives of Allergy and Immunology, 1995
- Human FcERI-IgG and humanized anti-IgE monoclonal antibody MaE11 block passive sensitization of human and rhesus monkey lungJournal of Allergy and Clinical Immunology, 1994
- Determining a minimal important change in a disease-specific quality of life questionnaireJournal of Clinical Epidemiology, 1994
- Inflammatory cells in the airways in mild asthma.BMJ, 1988
- Late Phase ReactionsAllergy and Asthma Proceedings, 1986
- The late phase of the immunoglobulin E-mediated reaction: a link between anaphylaxis and common allergic disease?Journal of Allergy and Clinical Immunology, 1982
- The late phase of the immediate wheal and flare skin reaction. Its dependence upon IgE antibodies.Journal of Clinical Investigation, 1976